Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 8Breast 8Gastrointestinal 7Tumor-Agnostic 6Thoracic 3Lymphoid 3Gynecologic 3Other 2Dermatologic 2CNS 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Dyspnea 1Cardiotoxicity 1

Interventions

Bortezomib 20Blood Specimen Collection 9Surveys and Questionnaires 8Lenalidomide 8Dexamethasone 8pomalidomide 6daratumumab 6Flow Cytometry 6Immunoenzyme Techniques 5Biopsy 5plerixafor 4idecabtagene vicleucel 4carfilzomib 4Standard of Care 4Polymerase Chain Reaction 4Amplified Fragment Length Polymorphism Analysis 4Specimen Handling 3Psychiatric Rehabilitation 3Patient Reported Outcome Measures 3Microarray Analysis 3Melphalan 3Magnetic Resonance Spectroscopy 3Interviews as Topic 3Drug Therapy 3Data Collection 3Cytogenetic Analysis 3Chromatin Immunoprecipitation Sequencing 3talquetamab 2selinexor 2belantamab mafodotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Hematologic Tests × Plasma cell × Clear all
NCT04827563 2026-03-04

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

University of Chicago

Terminated
50 enrolled
OtherPlasma cell

Dyspnea, Multiple Myeloma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡